Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine

Tohoku Journal of Experimental Medicine

Volumn 208, Issue 3, 2006, Pages 203-212

  Kuralay, Filiz ^a   Altekin, Emel ^a   Yazlar, Ayten Sayin ^a   Onvural, Banu ^a   Goldeli, Ozhan ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

C reactive protein; Nitric oxide; Percutaneous transluminal coronary angioplasty; Trimetazidine; Tumor necrosis factor

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; NITRITE; REACTIVE OXYGEN METABOLITE; TRIMETAZIDINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MALE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY DISEASE; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; NITRATES; NITRITES; REACTIVE OXYGEN SPECIES; TIME FACTORS; TREATMENT OUTCOME; TRIMETAZIDINE; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 33644542154     PISSN: 00408727     EISSN: None     Source Type: Journal    
DOI: 10.1620/tjem.208.203     Document Type: Article

References (76)

1. Albertine, K.H., Weyrich, A.S., Ma, X.L., Lefer, D.J., Becker, L.C. & Lefer, A.M. (1994) Quantification of neutrophil migration following myocardial ischemia and reperfusion in cats and dogs. J. Leukocyte Biol., 55, 557-566.
2. Ambrosio, G. & Tritto, I. (1998) How important is oxidative stress in ischemia, reperfusion and heart failure? Dialog Cardiovasc. Med., 38, 676-684.
3. Arnal, J.F., Warin, L. & Michel, J.B. (1992) Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J. Clin. Invest., 90, 647-652.
4. Azar, R.R., McKay, R.G., Kiernan, F.J. & Seecharran, B. (1997) Coronary angioplasty induces a systemic inflamatory response. Am. J. Cardiol., 80, 1476-1478.
5. Balligand, J.L., Ungureanu-Longrois, D., Simmon, W.W. & Pimental, D. (1994) Cytokine-iNOS expression in cardiac myocytes: characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J. Biol. Chem., 269, 27580-27588.
6. Bank, N., Aynedjian, H.S. & Khan, G.A. (1994) Mechanism of vasoconstruction induced by chronic inhibition of nitric oxide in rats. Hypertension, 24, 322-328.
7. Baumert, H., Faure, J.P., Zhang, K., Petit, I., Goujon, J.M., Dutheil, D., Favreau, F., Barriere, M., Tillement, J.P., Mauc, G., Papadopoulos, V. & Hauer, T. (2004) Evidence for a mitochondrial impact of trimetazidine during cold ischemia and reperfusion. Pharmacology, 71, 25-37.
8. Baylis, C., Mitruka, B. & Deng, A. (1992) Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J. Clin. Invest., 90, 278-281.
9. Belardinelli, R. & Purcaro, A. (2001) Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur. Heart J., 22, 2164-2170.
10. Belcher, P.R., Drake-Holland, A.J., Hynd, J.W & Noble, M.I. (1993) Effects of trimetazidine on in vivo coronary arterial platelet trombosis. Cardiovasc.Ther., 7, 149-157.
11. Birand, A., Kudaiberdieva, G.Z., Batyraliev, T.A., Akgul, F. & Saliu, S. (1998) Relationship between components of heart rate variability and doppler echocardiographic indices of left ventricular systolic performance in patients with coronary artery disease. Int. J. Angiol., 7, 244-248.
12. Bories, P.N. & Bories, C. (1995) Nitrate determination in biological fluids by an enzymatic one step assay with nitrate reductase. Clin. Chem., 41, 904-907.
13. Brottier, L., Barat, J.L., Combe, C., Boussens, B., Bonnet, J. & Bricaud, H. (1990) Therapeutic value of a cardio protective agent in patients with severe ischaemic cardiomyopathy. Eur. Heart J., 11, 207-212.
14. Camussi, G., Albano, E., Tetta, C. & Bussolino, F. (1991) The molecular action of tumor necrosis factor alpha. Eur. J. Biochem., 202, 3-14.
15. + -ATPase activity? Cardiovasc. Res., 47, 637-639.
16. Demaison, L., Fantini, E. & Sentex, E. (1995) Trimetazidine: In vitro influence on heart mitochondrial function. Am. J. Cardiol., 76, 31B-37B.
17. Di Pasquale, P., Lo Verso, P., Bucca, V., Connizzaro, S., Scalzo, S., Maringhini, G. (1999) Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc. Drugs Ther., 13, 423-428.
18. Doehner, W. (1999) Cytoprotection in acute myocardial infarction. Int. J. Cardiol., 72, 1-2.
19. El Banani, H., Bernard, M. & Baetz, D. (2000) Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low-and zero-flow ischemia. Cardiovasc. Res., 47, 688-696.
20. Fabiani, J.N., Ponzio, O., Emerit I., Massonet-Castel, S., Paris, M. & Chevaller, P. (1992) Cardioprotective effect of trimetazidine during coronary artery graft surgery. J. Cardiovasc. Surg., 33, 486-491.
21. Fantini, E., Athias, P., Demaison, L. & Grynberg, A. (1997) Protective effects of trimetazidine on hypoxic cardiac myocytes from the rat. Fundam. Clin. Pharmacol., 11, 427-439.
22. French, W.J. (2000) Trends in acute myocardial infarction management: use of National Registry of Myocardial Infarction in quality improvement. Am. J. Cardiol., 85, 5B-9B.
23. Folmes, C.D., Clanachan, A.S. & Lopaschuk, G.D. (2005) Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr. Atheroscler. Rep., 7, 63-70.
24. Fox, K.A. (2000) Acute coronary syndromes: Presentation-clincal spectrum and management. Heart, 84, 93.
25. Girgin, F., Tuzun, S., Demir, A., Kuralay, F., Ozutemiz, O. & Tanyalcin, T. (1999) Cytoprotective effects of trimetazidine in carmustine cholestasis. Exp. Toxicol. Pathol., 51, 326-329.
26. Gluckman, T.L., Grossman, J.E., Folts, J.D. & Kruse-Elliote, K.T. (2000) Regulation of leukocyte function by nitric oxide donors. J. Toxicol. Environ. Health A, 61, 9-26.
27. Green, L.C., Wagner, D.A., Glogowski, J., Skipper, P.L., Wishnok, J.S. & Tannenbaum, S.R. (1982) Analysis of nitrate, nitrite and 15 N nitrate in biological fluids. Anal. Biochem., 126, 131-138.
28. Grynberg, A. (2005) Effectors of fatty acid oxidation reduction: promising new anti-ischaemic agents. Curr. Pharm. Des., 11, 489-509.
29. Guamieri, C. & Muscari, C. (1993) Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology, 46, 324-331.
30. Halliwil, J.R., Minson, C.T. & Joyner, M.J. (2000) Effect of systemic nitric oxyde synthase inhibition on postexercise hypotension in humans. J. Appl. Physiol., 89, 1830-1836.
31. Heindland, U.E., Heintzen, M.P., Schwartzkopff, B. & Strauer, B.E. (2000) Preconditioning during percutaneous transluminal coronary angioplasty by endogenous and exogenous adenosine. Am. Heart J., 140, 813-820.
32. Josephy, C., Khalamizer, V., Viskoper, J.R., Iania, A., Manevich, I., London Jafari, J., Magen, E., Wollman, Y. & Reisin, L. (2003) Impaired nitric oxide production, brachial artery reactivity of fish oil in offspring of ischaemic heart disease patients. Br. J. Biomed. Sci., 20, 144-148.
33. Kaminski, K.A., Bonda, T.A., Korecki, J. & Musial, W.J. (2002) Oxidative stress and neutrophil activation-the two keystones of ischemia/ reperfusion injury. Int. J. Cardiol., 86, 41-59.
34. Kanko, M., Maral, H., Akbas, M.H., Ozden, M., Bulbul, S., Omay, O., Yavuz, S. & Berki, K.T. (2005) Protective effects of clopidogrel on oxidant damage in a rat model of acute ischemia. Tohoku J. Exp. Med., 205, 133-139.
35. Kantor, P.F., Lucien, A, Kozak, R. & Lopaschuk, G.D. (2000) The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res., 86, 580-588.
36. Kataoka, C., Egashira, K., Ishibashi, M., Inoue, S., Ni, W., Hiasa, K.I., Kitan, S., Usui, M. & Takeshita, A. (2003) Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. Am. J. Physiol. Heart Circ. Physiol., 30, 522-528.
37. Kay, L., Finelli, C. & Aussedat, J. (1995) Improvement of long term preservation of the isolated arrested rat heart by trimetazidine: effects of the energy state and mitochondrial function. Am. J. Cardiol., 76, 45B-49B.
38. Kloner, R.A., Giacomelli, F. & Alker, K.J. (1991) Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia-reperfusion. Circulation, 84, 1758-1772.
39. Kobayashi, N., Ohmura, N. & Nakada, I. (1997) Further ST elevation at reperfusion by direct percutaneous transluminal coronary angioplasty predicts poor recovery of left ventricular systolic function in anterior wall AMI Am. J. Cardiol., 79, 862-866.
40. Kober, G., Pennaforte, S., Buck, T., Sievert, H. & Vallbracht, C. (1993) Myocardial cytoprotection during percutaneous transluminal' coronary angioplasty. Eur. Heart J., 14, 6-11.
41. Kowalski, J., Pawlicki, L., Baj, Z., Pasnik, J. & Olejniczak, J. (2000) Effect of trimetazidine on biological activity of neutrophils in patients with transient myocardial ischemia induced by exercise testing. Pol. Merkuriusz Lek., 9, 548-551.
42. Koyanagi, M., Egashira, K., Kitamoto, S., Ni, W., Shimokawa, H., Takeya Yoshimura, T. & Takeshita, A. (2000a) Role of chemoattractant protein-I in cardiovascular remodelling induced by chronic blockade of nitric oxide synthesis. Circulation, 102, 2243-2248.
43. Koyanagi, M., Egashira, K., Kubo-Inoue, M., Usui, M., Kitamoto, S., Tomi, H., Shimokawa, H. & Takeshita, A. (2000b) Role of transforming growth factor in cardiovascular inflammatory changes induced by chronic inhibition of nitric oxide synthesis. Hypertension, 35, 86-90.
44. Kuralay, F., Yildiz, C., Ozutemiz, O., Islekel, H., Caliskan, S., Bingol, B. & Ozkal, S. (2003) Effects of trimetazidine on acetic acid-induced colitis in female Swiss rats. J. Toxicol. Environ. Health A, 24, 3169-3179.
45. Levy, S. (1995) Combination therapy of trimetazidine with coronary artery disease. Group of South of France. Am. J. Cardiol., 76, 12B-16B.
46. Lopaschuk, G.D. (2001) Optimising cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coronary Artery Dis., 12, 8-11.
47. Lu, C., Dabrowski, P., Fragasso, G. & Chierchia, S.L. (1998) Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am. J. Cardiol., 82, 898-901.
48. Lucchesi, B.R. (1990) Modulation of leukocyte-mediated myocardial reperfusion injury. Annu. Rev. Physiol., 52, 561-576.
49. Liuzzo, G., Biasucci, L.M. & Gallimore, J.R. (1994) The prognostic value of C-reactive protein and serum amyloid A protein in sever unstable angina. N. Engl. J. Med., 331, 417-424.
50. Manchanda, S.C. & Krishnaswami, S. (1997) Combination of treatment with trimetazidine and diltiazem in stable angina pectoris. Heart, 78, 353-357.
51. Matsumara, K., Jeremy, R.W., Schaper, J. & Becker, L.C. (1998) Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation, 97, 795-804.
52. Michaelides, A.P., Bonoris, P.E., Psaros, T.K., Papadopoulos, P.D. & Toutouzas, P.K. (1989) Beneficial effects of trimetazidine in patients with stable angina pectoris under beta-blocker treatment. Current Therapeutic Research, 46, 565-576.
53. Michaelides, A.P. & Dimopoulos, K. (1997) Antianginal efficacy of the combination of trimetazidine-propanolol compared with isosorbide-dinitrate-propanolol in patients with stable angina. Clin. Drug Invest., 13, 8-14.
54. Noble, M.I., Belcher, P.R. & Drake - Holland, A.J. (1995) Limitation of infarct size by trimetazidine in the rabbit. Am. J. Cardiol., 76, 41B-44B.
55. Numaguchi, K., Egashira, K., Takemoto, M., Kadokami, T., Shimokawa, I., Sueshi, K. & Takeshita, A. (1995) Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension, 26, 957-962.
56. Opie, L.H. & Boucher, E (1995) Trimetazidine and myocardial ischemic contracture in isolated rat heart. Am. J. Cardiol., 286, 97-110.
57. Pauly, D.F. & Pepine, C.J. (2004) Ischemic heart disease: metabolic approaches to management. Clin. Cardiol., 27, 439-441.
58. Ridker, P.M., Cushman, M. & Stampfer, M.J. (1997) Inflammation, aspirin and the risk of cardiovascular disease in apparently healty men. N. Engl. J.Med., 336, 973-979.
59. Rogacka, D., Guzik, P. & Wykretowicz, A. (2000) Efficacy and tolerance of trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina. TRIMPOL I, a multicenter study. Presse Med., 11, 171-177.
60. Seo, H.G., Takata, I., Nakamura, M., Tatsumi, H., Suzuki, K., Fujii, J. & Taniguchi, N. (1995) Induction of nitric oxide synthase and concomitant suppression of superoxide dismutases in experimental colitis in rats. Arch. Biochem. Biophys., 324, 41-47.
61. Stanley, W.C. & Marzilli, M. (2003) Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam. Clin. Pharmacol., 17, 133-145.
62. Stanley, W.C. (2004) Myocardial energy metabolism during ischemia and the mechanisms of metabolic therapies. J. Cardiovasc. Pharmacol. Ther., 11, S31-S45.
63. Steg, P.G., Grollier, G., Gallay, P., Morice, M., Karrillon, G.J., Benamer, H., Kempf, C., Laperche, T., Arnaud, P., Sellier, P., Bourguignon, C. & Harpey, C. (LIST Study Group) (2001) A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int. J. Cardiol., 77, 263-273.
64. Sumeray, M.S., Rees, D.D. & Yellon, D.M. (2000) Infarct size and nitric oxide synthase in murine myocardium. J. Mol. Cell Cardiol., 32, 35-42.
65. Szwed, H., Hradec, J. & Preda, I. (2001a) Anti-ischaemic efficacy and tolerability of trimetazidine administered to patients with angina pectoris: results of three studies. Coron. Artery Dis., 12, 25-28.
66. Szwed, H., Sadowski, Z., Elikowski, W., Koronkiewicz, A., Mamcarz, A., Orszulak, W., Skibinska, E., Szymczak, K., Swiatek, J. & Winter, M. (2001b) Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur. Heart J., 22, 2267-2274.
67. Tabbi-Anneni, I., Lucien A. & Grynberg, A. (2003) Trimetazidine effect on phospholipid synthesis in ventricular myocytes: cosequences in alpha-adrenergic signaling. Fundam. Clin. Pharmacol., 17, 51-59.
68. Tamam, Y., Iltumur, K. & Apak, I. (2005) Assesment of Acute phase proteins in acute ischemic stroke. Tohoku J. Exp. Med., 206, 91-98.
69. The EMIP-FR Group (2000) Effect of 48 h intravenous trimetazidine on short and long term outcomes of patients with acute myocardial infarction with and without thrombolytic therapy. European Heart J., 21, 1537-1545.
70. Tikhaze, A.K., Lankin, V.Z., Zharova, E.A. & Kolvycheva, S.V. (2000) Trimetazidine as indirect antioxidant. Bull. Exp. Biol. Med., 130, 951-953.
71. Veitch, K., Maisin, L & Hue, L. (1995) Trimetazidine effects on the damage to mitochondrial functions caused by ischemia and reperfusion. Am. J. Cardiol., 76, 25B-30B.
72. Wildhirt, S.M., Weismuellr, S., Schulze, C. & Conrad N. (1999) Inducible nitric oxide synthase activation after ischemia/reperfusion contributes to myocardial dysfunction and extent of infarct size in rabbits: evidence for a late phase of nitric oxide-mediated reperfusion injury. Cardiovasc. Res., 43, 698-711.
73. Williams, F.M., Tanda, K., Kus, M. & Williams, T.J. (1993) Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J. Cardiovasc. Pharmacol., 22, 828-833.
74. Young, L.H., Russel, R.R., Yin, R., Caplan, M.J., Ren, J., Bergeron, R., Shulman, G.I. & Sinusas, A.J. (1999) Regulation of myocardial glucose uptake and transport during ischemic and energetic stress. Am. J. Cardiol., 83, 25H-30H.
75. Zhao, Z.Q., Nakamura, M., Wang, N.P., Velez, D.A., Hewan-Lowe, K.O., Guyton, R.A. & Vinten-Johansen, J. (2000) Dynamic progression of contractile and endothelial dysfunction and infarct extension in the late phase of reperfusion. J. Surg. Res., 94, 133-144.
76. Zhao, Q., Egashira, K., Inoue, S., Usui, M., Kitamoto, S., Ni, W., Ishibashi, M., Hiasa, K., Ichiki, T., Shibuya, M. & Takeshita, A. (2002) Vascular endotelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in arat model of long term inhibition of nitric oxide synthesis. Circulation, 105, 1110-1115.